Steiner G, Shovman O, Skriner K, Gilburd B, Langevitz P, Miholits M, Hoet R, Levy Y, Zandman-Goddard G, Hoefler E, Smolen J S, Shoenfeld Y
Department of Internal Medicine III, University of Vienna, Austria.
Clin Exp Rheumatol. 2002 Jul-Aug;20(4):517-24.
Anti-RA33 antibodies occur in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and mixed connective tissue disease (MCTD) and target the A2/B1 protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex 4 which forms part of the spliceosome. The aim of the present study was to evaluate the immune response and pathological features induced in mice immunized with anti-RA33 antibodies or patient-derived recombinant single-chain variable fragments (scFv) of anti-RA33 antibodies.
In the first set of the experiment, two strains of mice (C57BL/6J and BALB/c) were immunized with IgG preparations obtained from two patients with RA and one normal donor. One of the patients had high titer anti-RA33 antibodies; the other one showed weak borderline reactivity. In the second set of the experiment three groups of C57BL/6J mice were immunized, respectively, with affinity-purified (AP) anti-RA33 antibodies, scFv of anti-RA33 antibodies and normal human IgG. The immunological response induced in immunized mice was studied by immunoblotting and line immunoassay (LIA). The presence of arthritis, serositis or myositis was assessed six-months following initial immunization.
While anti-RA33 antibodies developed in only two of the mice immunized with different human IgG fractions, anti-RA33 antibodies were clearly detected in 7 sera of 13 mice immunized with AP anti-RA33 antibodies three months after the boost immunization and, moreover, also in 2 sera of 13 mice immunized with scFv of anti-RA33 antibodies. In contrast, mice immunized with normal human IgG did not develop anti-RA33 antibodies. Interestingly, transient autoantibody production against another nuclear autoantigen, U1 snRNP, was observed in 3 C57BL/6J mice immunized with scFv and in 1 mouse immunized with AP autoantibodies. However, these immunological responses were not associated with pathological findings.
Active immunization of naive mice with AP anti-RA33 antibodies and scFv of anti-RA33 antibodies resulted on the one hand in the production of murine anti-RA33 antibodies and led, on the other hand, to transient "autoantibody spread" to snRNP component of the spliceosome and other nuclear autoantigens. This "autoantibody spread" probably reflected disregulation of the idiotypic anti-idiotypic cascade.
抗RA33抗体出现在类风湿关节炎(RA)、系统性红斑狼疮(SLE)和混合性结缔组织病(MCTD)患者中,其靶标是不均一核糖核蛋白(hnRNP)复合物4的A2/B1蛋白,该复合物是剪接体的一部分。本研究的目的是评估用抗RA33抗体或患者来源的抗RA33抗体重组单链可变片段(scFv)免疫小鼠后诱导的免疫反应和病理特征。
在第一组实验中,用从两名RA患者和一名正常供体获得的IgG制剂免疫两株小鼠(C57BL/6J和BALB/c)。其中一名患者具有高滴度抗RA33抗体;另一名患者显示出弱阳性反应。在第二组实验中,将三组C57BL/6J小鼠分别用亲和纯化(AP)抗RA33抗体、抗RA33抗体的scFv和正常人IgG进行免疫。通过免疫印迹和线性免疫分析(LIA)研究免疫小鼠中诱导的免疫反应。在初次免疫后六个月评估是否存在关节炎、浆膜炎或肌炎。
在用不同人IgG组分免疫的小鼠中,只有两只产生了抗RA33抗体,而在用AP抗RA33抗体免疫的13只小鼠中,有7只在加强免疫三个月后血清中明显检测到抗RA33抗体,此外,在用抗RA33抗体的scFv免疫的13只小鼠中,也有2只血清中检测到抗RA33抗体。相比之下,用正常人IgG免疫的小鼠未产生抗RA33抗体。有趣的是,在用scFv免疫的3只C57BL/6J小鼠和用AP自身抗体免疫的1只小鼠中,观察到针对另一种核自身抗原U1 snRNP的短暂自身抗体产生。然而,这些免疫反应与病理结果无关。
用AP抗RA33抗体和抗RA33抗体的scFv对未免疫小鼠进行主动免疫,一方面导致产生鼠抗RA33抗体,另一方面导致向剪接体的snRNP组分和其他核自身抗原的短暂“自身抗体扩散”。这种“自身抗体扩散”可能反映了独特型-抗独特型级联的失调。